Religare revises ‘high conviction target’ to hold, sees 11% upside as midcap stock nears 52-week high; do you own?
Shares of Jyothy Labs neared their 52-week high levels of ₹466 after reporting decent July-September quarter results for fiscal 2023-24 (Q2FY24). Domestic brokerage firm Religare Broking has revised its rating on the midcap stock to ‘accumulate’ or ‘continue to hold’ after the ‘high conviction’ target was achieved at 27 per cent by the end of September 2023.
At a current market price (CMP) of ₹419, Religare has given a target price of ₹466 for Jyothi Labs and sees a potential upside of 11.2 per cent. On Thursday, shares of Jyothi Labs settled 4.29 per cent lower at RS 439.20 apiece on the BSE.
Jyothy Labs Q2 Results
Jyothy Labs reported a consolidated net profit of ₹103.98 crore in the September quarter, up 59.1 per cent from ₹65.35 crore registered a year ago. The company’s revenue from operations in the second quarter of current fiscal stood at ₹732.34 crore, registering a growth of 11.09 per cent, compared to ₹659.20 crore in the year-ago period.
The company’s earnings before interest, tax, depreciation and amortization (EBIDTA) for September quarter stood at ₹135 crore rising 69 per cent year-on-year. The EBIDTA margin was at 18.5 per cent in the quarter-under-review.
“The demand across our product portfolio has been stable. The inflationary environment has been a constant pressure on the consumption of FMCG products, however given our business potential, we continue to expand our distribution footprint across India and further strengthen our brands which has resulted in consistent business growth.” said M R Jyothy, Managing Director, Jyothy Labs Limited.
Religare’s outlook on Jyothy Labs
‘’Jyothi Labs reported decent Q2FY24 results led by growth across most of its segments, strong volume growth and healthy spends on advertisements. Further, the management plan is to drive volume led growth, invest behind its core brands by innovating more products and adding categories as well as continue to strengthen distribution reach,” said the brokerage in its report.
‘’On the financials, revenue/EBITDA is estimated to grow at 15 per cent/42.5 per cent CAGR over FY23-25E as we are optimistic on the growth prospect of Jyothy Labs and revise rating to Accumulate with target price to ₹466,” said Religare Broking.
Milestone Alert!Livemint tops charts as the fastest growing news website in the world 🌏 Click here to know more.
Download Finplay News App to get Daily Market Updates.
More
Less
Updated: 16 Nov 2023, 07:56 PM IST
Ganesh
http://ganesh@finplay.inFinance enthusiast, Mutual fund expert.